Skip to main content
Log in

Defining tetrahydrobiopterin (BH4)-responsiveness in PKU

  • Editorial
  • Published:
Journal of Inherited Metabolic Disease

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  • Burnett JR (2007) Sapropterin dihydrochloride (Kuvan/Phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria. IDrugs 10(11): 805–813.

    PubMed  CAS  Google Scholar 

  • Fiege B, Blau N (2007) Assessment of tetrahydrobiopterin (BH4)-responsiveness in phenylketonuria. J Pediatr 150: 627–630.

    Article  PubMed  CAS  Google Scholar 

  • Levy L, Milanowski A, Chakrapani A, et al (2007) Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomized placebo-controlled study. Lancet 370: 504–510.

    Article  PubMed  CAS  Google Scholar 

  • Zurflüh MR, Zschocke J, Lindner M, et al (2008) Molecular genetics of tetrahydrobiopterin responsive phenylalanine hydroxylase deficiency. Hum Mutat 29(1): 167–175

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nenad Blau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blau, N. Defining tetrahydrobiopterin (BH4)-responsiveness in PKU. J Inherit Metab Dis 31, 2–3 (2008). https://doi.org/10.1007/s10545-007-9979-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-007-9979-1

Navigation